Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;111(2):205-212.
doi: 10.5935/abc.20180138.

Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review

[Article in English, Portuguese]
Andréa de Melo Leite  1   2 , Ariane Vieira Scarlatelli Macedo  3 , Antonio José Lagoeiro Jorge  1 , Wolney de Andrade Martins  1
Affiliations
Review

Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review

[Article in English, Portuguese]
Andréa de Melo Leite et al. Arq Bras Cardiol. 2018 Aug.

Abstract

Breast cancer is the most frequently diagnosed tumor in women worldwide, with a significant impact on morbidity and mortality. Chemotherapy and hormone therapy have significantly reduced mortality; however, the adverse effects are significant. Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications. The objective of this study was to evaluate the role of aspirin in reducing the incidence of breast cancer and to evaluate the impact of its use on morbidity and mortality and reduction of cardiovascular events as adjuvant therapy during breast cancer treatment with selective estrogen receptor modulators. A systematic review was performed using the PRISMA methodology and PICO criteria, based on the MEDLINE, EMBASE and LILACS databases. The original articles of clinical trials, cohort, case-control studies and meta-analyses published from January 1998 to June 2017, were considered. Most studies showed an association between the use of selective estrogen receptor modulators and the increase in thromboembolic events. The studies suggest a protective effect of aspirin for cardiovascular events during its concomitant use with selective estrogen receptor modulators and in the prevention of breast cancer. This systematic review suggests that aspirin therapy combines the benefit of protection against cardiovascular events with the potential reduction in breast cancer risk, and that the evaluation of the benefits of the interaction of endocrine therapy with aspirin should be further investigated.

PubMed Disclaimer

Conflict of interest statement

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Flowchart of the evaluated studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ch Yiannakopoulou E. Interaction of salicylates and the other nonsteroidal anti-inflammatory agents with breast cancer endocrine treatment systematic review. Am J Clin Oncol. 2015;38(6):641–644. - PubMed
    1. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G. Women's Health Initiative Breast cancer and nonsteroidal anti-inflammatory drugs prospective results from the Women's Health Initiative. Cancer Res. 2003;63(18):6096–6101. - PubMed
    1. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs a meta-analysis. J Natl Cancer Inst. 2008;100(20):1439–1447. - PubMed
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses the PRISMA statement. Ann Intern Med. 2009;151(4):264–269. - PubMed
    1. Cosman F, Lindsay R. Selective estrogen receptor modulators clinical spectrum. Endocr Rev. 1999;20(3):418–434. - PubMed

MeSH terms

Substances

-